Empagliflozin DIABETES » SGLT-2 INHIBITORS INDICATION Glifo is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus and to reduce the risk of cardiovascular death in adult patients with type 2 diabetes mellitus and established cardiovascular disease. DOSAGE AND ADMINISTRATION Age and Body Weight Initial […]
Empagliflozin Description Sodium-glucose co-transporter 2 (SGLT2) is the predominant transporter responsible for reabsorption of glucose from the glomerular filtrate back into the circulation. Empagliflozin is an inhibitor of SGLT2. By inhibiting SGLT2, Empagliflozin reduces renal reabsorption of filtered glucose and lowers the renal threshold for glucose, and thereby increases urinary glucose excretion. Presentation Empaglif 10 […]
Generic Name: EmpagliflozinDosage Form: TabletTG Name: Endocrine & Diabetes 1. What is Jardimet®?Jardimet® is a combination of Empagliflozin, a Sodium-glucose cotransporter-2 (SGLT2) inhibitor and Metformin Hydrochloride, a biguanide, indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both Empagliflozin and Metformin Hydrochloride is appropriate. 2. How […]
Generic Name: EmpagliflozinDosage Form: TabletsTG Name: Endocrine & Diabetes What is Jardian®?Jardian® is a preparation of Empagliflozin. Empagliflozin is a drug of the gliflozin class, approved for the treatment of type 2 diabetes in adults. It is an inhibitor of the sodium glucose co-transporter-2 (SGLT-2), and causes sugar in the blood to be excreted by the kidneys and eliminated […]
EmpagliflozinSGLT2 Inhibitor (Antidiabetic Preparations) Indication: • Emjard™ is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes (T2DM).• Emjard™ is also indicated to reduce the risk of cardiovascular death in adult patients with type 2 diabetes mellitus and established cardiovascular disease. Dosage & Administration: The recommended dose of […]